Miraca To Buy US Clinical Lab Testing Co. For $725M

Law360, New York (October 6, 2011, 3:25 PM EDT) -- Japan-based Miraca Holdings Inc. on Thursday announced plans to buy a unit of U.S. diagnostics provider Caris Life Sciences for $725 million in a bid to tap into the growing U.S. clinical lab testing market.

Miraca, Japan’s leading provider of clinical diagnostics and laboratory testing services, will acquire Caris Diagnostics Inc., the anatomic pathology business of Dallas, Texas-based Caris Life Sciences. The sale is expected to close by the end of the year, pending the spinoff that will combine Caris Life Sciences’ molecular profiling test unit...
To view the full article, register now.